Harmony Biosciences Holdings Stock News

These companies are expected to continue growing revenue at a rapid pace through 2027.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:10 PM EDT Company Participants Jeffrey Dayno - President, CEO & Director Sandip Kapadia - Executive VP, Chief Administrative Officer & CFO Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Presentation Pete Stavropoulos Biotech Analyst Welcome ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30 – September 3, 2025, at the Lisbon Congress Centre in Lisbon, Portugal. Poster presentations will highlight information from the company's investigation of EPX-1...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 4, 2025, at 2:10 p.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at...

Harmony Biosciences remains a Buy due to strong Wakix growth, profitability, and undervalued metrics despite recent setbacks. Upcoming catalysts—especially ZYN002 Phase 3 data in Fragile X—could drive significant upside, with >25% share price potential if successful, in my view. Pipeline diversification (pitolisant HD, GI, OX2R agonist, EPX-100) aims to offset Wakix patent expiry and expand lon...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Adam Zaeske - Executive VP & Chief Commercial Officer Brennan Doyle - VP & Head of Investor Relations Jeffrey M. Dayno - President, CEO & Director Kumar Budur - Executive VP and Chief Medical & Scientific Officer Sandip S.

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced plans to announce topline data from its phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome in Q3 2025. The company also announced 16% year-over-year revenue growth for WAKIX® in Q2 2025, driven by strong patient adds of 400 for the quarter, continuing its trajectory towar...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2025 financial results on Tuesday, August 5, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 5, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 833-316-248...